HC Wainwright Reiterates “Hold” Rating for Valeant Pharmaceuticals International, Inc. (NYSE:VRX)

HC Wainwright restated their hold rating on shares of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX) in a research report sent to investors on Friday, November 3rd. HC Wainwright currently has a $17.00 price objective on the specialty pharmaceutical company’s stock.

A number of other research firms have also recently commented on VRX. Zacks Investment Research cut shares of Valeant Pharmaceuticals International from a hold rating to a sell rating in a report on Thursday, October 12th. Stifel Nicolaus restated a buy rating and issued a $35.00 price target on shares of Valeant Pharmaceuticals International in a report on Thursday, August 10th. Piper Jaffray Companies set a $14.00 price target on shares of Valeant Pharmaceuticals International and gave the stock a sell rating in a report on Sunday, October 22nd. Vetr upgraded shares of Valeant Pharmaceuticals International from a strong sell rating to a sell rating and set a $12.46 price objective for the company in a report on Monday, September 18th. Finally, Cantor Fitzgerald set a $23.00 price objective on shares of Valeant Pharmaceuticals International and gave the company a buy rating in a report on Wednesday, August 16th. Five analysts have rated the stock with a sell rating, eleven have assigned a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. The company currently has a consensus rating of Hold and a consensus target price of $17.17.

Shares of Valeant Pharmaceuticals International (VRX) traded up $0.55 during midday trading on Friday, reaching $16.54. 21,460,634 shares of the company were exchanged, compared to its average volume of 17,934,104. The company has a debt-to-equity ratio of 4.84, a current ratio of 1.26 and a quick ratio of 1.03. The company has a market capitalization of $5,750.00, a P/E ratio of 2.53, a PEG ratio of 0.43 and a beta of -0.40. Valeant Pharmaceuticals International has a fifty-two week low of $8.31 and a fifty-two week high of $18.25.

COPYRIGHT VIOLATION WARNING: This piece was first posted by BBNS and is the sole property of of BBNS. If you are reading this piece on another website, it was stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this piece can be accessed at https://baseballnewssource.com/markets/valeant-pharmaceuticals-international-inc-vrx-receives-hold-rating-from-hc-wainwright-2/1755791.html.

In other Valeant Pharmaceuticals International news, Director John Paulson acquired 344,216 shares of the business’s stock in a transaction dated Thursday, November 16th. The stock was bought at an average price of $14.40 per share, with a total value of $4,956,710.40. Following the purchase, the director now owns 94,559 shares of the company’s stock, valued at $1,361,649.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 5.87% of the stock is currently owned by corporate insiders.

A number of large investors have recently bought and sold shares of the stock. Moors & Cabot Inc. raised its holdings in Valeant Pharmaceuticals International by 55.0% during the 3rd quarter. Moors & Cabot Inc. now owns 23,675 shares of the specialty pharmaceutical company’s stock valued at $337,000 after buying an additional 8,400 shares during the last quarter. Janney Montgomery Scott LLC raised its holdings in Valeant Pharmaceuticals International by 33.7% during the 3rd quarter. Janney Montgomery Scott LLC now owns 20,095 shares of the specialty pharmaceutical company’s stock valued at $288,000 after buying an additional 5,069 shares during the last quarter. Cubist Systematic Strategies LLC raised its holdings in Valeant Pharmaceuticals International by 9,253.2% during the 3rd quarter. Cubist Systematic Strategies LLC now owns 56,119 shares of the specialty pharmaceutical company’s stock valued at $804,000 after buying an additional 55,519 shares during the last quarter. AMP Capital Investors Ltd raised its holdings in Valeant Pharmaceuticals International by 6.3% during the 3rd quarter. AMP Capital Investors Ltd now owns 142,910 shares of the specialty pharmaceutical company’s stock valued at $2,043,000 after buying an additional 8,484 shares during the last quarter. Finally, Stifel Financial Corp raised its holdings in Valeant Pharmaceuticals International by 18.4% during the 3rd quarter. Stifel Financial Corp now owns 236,576 shares of the specialty pharmaceutical company’s stock valued at $3,384,000 after buying an additional 36,705 shares during the last quarter. Institutional investors own 48.49% of the company’s stock.

Valeant Pharmaceuticals International Company Profile

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Analyst Recommendations for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Manny Machado Could Change Positions or Uniforms
Manny Machado Could Change Positions or Uniforms
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Yankees and Marlins Continue Stanton Trade Talks
Yankees and Marlins Continue Stanton Trade Talks
Marlins Making Moves, Trade Dee Gordon to Seattle
Marlins Making Moves, Trade Dee Gordon to Seattle
Report: Astros Dallas Keuchel Pitched With Injured Foot
Report: Astros Dallas Keuchel Pitched With Injured Foot
Angels Sign Former Prospect with Braves Kevin Maitan
Angels Sign Former Prospect with Braves Kevin Maitan


Leave a Reply

 
© 2006-2017 BBNS.